Dressings Patents (Class 424/445)
-
Patent number: 10080823Abstract: The present disclosure relates to substrates associated with nitric oxide.Type: GrantFiled: November 17, 2010Date of Patent: September 25, 2018Assignee: Gearbox LLCInventors: Roderick A. Hyde, Muriel Y. Ishikawa, Leif T. Stordal, Lowell L. Wood, Jr.
-
Patent number: 10080816Abstract: This invention relates to a wound dressing, particularly to a stimuli responsive wound dressing comprising a lyophilized hyaluronic acid (HA) hydrogel, and a plurality of devices embedded within said lyophilized hyaluronic acid hydrogel. Each of the plurality of devices including chitosan and hypromellose and may be formed as biofilms and/or electrospun fiber mats.Type: GrantFiled: June 5, 2015Date of Patent: September 25, 2018Assignee: University of the Witwatersrand, JohannesburgInventors: Viness Pillay, Yahya Essop Choonara, Pradeep Kumar, Lisa Claire Du Toit, Naeema Mayet
-
Patent number: 10076586Abstract: A solid wound dressing material comprising: at least about 5 wt % collagen; from about 6 wt % to about 9 wt % polyvinylpyrrolidone triiodide (PVP-I); and from 0 wt % to about 20 wt % water; wherein the weight percentages are based on the dry weight of the composition. Also provided are methods of making such materials, and wound dressings comprising such materials. In another aspect the invention provides a solid wound dressing material comprising: at least about 5 wt % collagen; from about 10 wt % to about 90 wt % Cadexomer iodine; and from 0 wt % to about 20 wt % water, wherein the weight percentages are based on the dry weight of the composition. Also provided are wound dressings comprising the materials.Type: GrantFiled: May 1, 2013Date of Patent: September 18, 2018Assignee: KCI USA, INC.Inventor: Lorna McInroy
-
Patent number: 9994488Abstract: An ultrafine continuous fibrous ceramic filter, which comprises a filtering layer of a fibrous porous body, wherein the fibrous porous body comprises continuous ultrafine fibers of metal oxide which are randomly arranged and layered, and powdery nano-alumina incorporated into the ultrafine fibers or coated thereon, the ultrafine fibers being obtained by electrospinning a spinning solution comprising a metal oxide precursor sol-gel solution, and optionally, a polymer resin, and sintering the electrospun fibers, in which the ultrafine fibers have an average diameter of 10˜500 nm, and the fibrous porous body has a pore size of maximum frequency ranging from 0.05 to 2 ?m, exhibits high filtration efficiency at a high flow rate, and can be regenerated.Type: GrantFiled: May 4, 2016Date of Patent: June 12, 2018Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Seong Mu Jo, Dong Young Kim, Sung-Yeon Jang, Jeong Joo Choo
-
Patent number: 9956245Abstract: The present invention relates to a gel composition comprising a glucan and a gelling agent, said composition having a melting point (gel to sol) above 37° C., as well as to the uses of this composition in therapy, in particular in wound healing.Type: GrantFiled: November 29, 2011Date of Patent: May 1, 2018Assignee: BIOTECH PHARMACON ASAInventors: Rolf Engstad, Dag-Eirik Ramsøy, Erik Steene
-
Patent number: 9925210Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.Type: GrantFiled: February 4, 2015Date of Patent: March 27, 2018Assignee: Tricol Biomedical, Inc.Inventors: Simon McCarthy, Barbara McGrath, Sam Kuhn, Jess Kimball, Michael Stolten, Amanda Bennett
-
Patent number: 9867900Abstract: The present invention relates to a fibrous haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilized by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.Type: GrantFiled: May 28, 2014Date of Patent: January 16, 2018Assignee: Medtrade Products LimitedInventors: Craig Hardy, Andrew Hoggarth, June Gladman
-
Patent number: 9855313Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.Type: GrantFiled: June 23, 2016Date of Patent: January 2, 2018Assignee: MUSC Foundation for Research DevelopmentInventors: Gautam Ghatnekar, Robert Gourdie, Jane Jourdan
-
Patent number: 9821084Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.Type: GrantFiled: June 10, 2010Date of Patent: November 21, 2017Assignee: Virginia Commonwealth UniversityInventors: Robert F. Diegelmann, Kevin R. Ward, Marcus E. Carr, Gary Lee Bowlin
-
Patent number: 9821063Abstract: Pharmaceutical compositions comprising an aminoglycosidic antibiotic and at least one zinc-chelating agent in a specified concentration, and methods of inhibiting bacterial colonization, biofilm formation and if treating bacterial infections utilizing the compositions are provided. Topical formulations suitable for wound care, and surface-applicable formulations suitable for medical, industrial and household disinfecting needs are also described.Type: GrantFiled: April 16, 2014Date of Patent: November 21, 2017Assignee: University of CincinnatiInventors: Andrew B. Herr, Gary Young
-
Patent number: 9808553Abstract: Haemostatic wound dressings are described. The dressings comprise a non-colloidal porous dressing material, and a plurality of fibrinogen-binding peptides immobilised to the non-colloidal porous dressing material, wherein each fibrinogen-binding peptide comprises: an amino acid sequence Gly-Pro-Arg-Xaa (SEQ ID NO: 1) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Val, preferably Pro, Sar, or Leu; or an amino acid sequence Gly-His-Arg-Xaa (SEQ ID NO: 2) at an amino-terminal end of the peptide, wherein Xaa is any amino acid other than Pro. The dressings are able to accelerate haemostasis without requiring enzymatic activity. In particular, the dressings to do not rely on the action of exogenous thrombin, and can be stored long-term at room temperature in solution. Methods of making the dressings, and use of the dressings to control bleeding are also described.Type: GrantFiled: February 1, 2013Date of Patent: November 7, 2017Assignee: HAEMOSTATIX LIMITEDInventors: Greg Walker, Sarah Margaret Middleton
-
Patent number: 9795706Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.Type: GrantFiled: April 4, 2016Date of Patent: October 24, 2017Assignee: Advanced Bio-Technologies, Inc.Inventor: Paul Guilbaud
-
Patent number: 9782381Abstract: Molecular target for healing or treating wounds and, in particular chronic, human wounds, are described. The molecular target is PTPRK, or a protein 50% homologous therewith, and which retains the same activity as PTPRK protein. Further, methods and novel therapeutics are described for treating said wounds.Type: GrantFiled: May 9, 2016Date of Patent: October 10, 2017Assignee: University College Cardiff Consultants LimitedInventors: Wenguo Jiang, Keith Harding
-
Patent number: 9771904Abstract: Provided are a self-cleaning air filtering material and a preparation method therefor. The air filtering material comprises: a submicron fiber layer (2) at an inflow surface for surface filtration, a supporting area (3) for supporting and a mixed area (5) between the submicron fiber layer (2) and the supporting area (3), wherein the mixed area (5) is formed by contacting and mixing part of the fibers in the submicron fiber layer (2) and the supporting area (3) with each other during the one-step formation of the submicron fiber layer (2) and the supporting area (3) by passing through a double-layer headbox.Type: GrantFiled: April 25, 2012Date of Patent: September 26, 2017Assignee: Fibrway Materials Science & Technology Development Co., Ltd.Inventors: Jian Hu, Yun Liang, Yi Wang, Jingshan Zeng
-
Alimentary protein-based scaffolds (APS) for wound healing, regenerative medicine and drug discovery
Patent number: 9744262Abstract: The invention provides engineered biomaterials derived from plant products. The engineered biomaterials are useful for biomedical applications. The engineered biomaterials are able to support the growth of animal calls.Type: GrantFiled: June 11, 2014Date of Patent: August 29, 2017Assignee: DREXEL UNIVERSITYInventors: Peter I. Lelkes, Dara L. Woerdeman, Leko Lin, Anat Katsir -
Patent number: 9730956Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.Type: GrantFiled: March 10, 2015Date of Patent: August 15, 2017Assignee: Nitric Solutions, Inc.Inventors: Alex Stenzler, Christopher C. Miller, Gilly Regev-Shoshani
-
Patent number: 9725574Abstract: The present disclosure provides a polyester-based plasticizer for resin, which is represented by Formula 1.Type: GrantFiled: March 18, 2015Date of Patent: August 8, 2017Assignee: CJ CHEILJEDANG CORPORATIONInventors: Young Lyeol Yang, Ji Ho Hwang, Do Yong Shim
-
Patent number: 9662374Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.Type: GrantFiled: February 19, 2016Date of Patent: May 30, 2017Assignee: BIOM'UPInventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
-
Patent number: 9655967Abstract: The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) activity or expression. Blockade of FAK is sufficient to prevent mechanical and inflammatory stimuli from activating MCP-1 pathways. In addition to these chemokine-mediated mechanisms, inhibition of FAK may control fibrosis by blocking fibroblast collagen production. Pharmacologic blockade of FAK significantly reduces scar formation in vivo.Type: GrantFiled: December 5, 2012Date of Patent: May 23, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Geoffrey C. Gurtner, Michael T. Longaker, Victor W. Wong
-
Patent number: 9572907Abstract: The present disclosure relates to implantable medical devices containing a polymeric film layer containing glycerol and at least one biopolymer.Type: GrantFiled: October 1, 2010Date of Patent: February 21, 2017Assignee: Covidien LPInventors: Joshua Stopek, Amin Elachchabi
-
Patent number: 9555157Abstract: A method of inducing hemostasis in a wound. A hemostatic product is applied to a wound. The hemostatic product includes at least one hemostasis component. The hemostatic product is retained with respect to the wound by positioning a hydrogel material at least partially over the hemostatic product. At least a portion of the hemostatic product is dissolved. Hemostasis is induced in the wound with the at least one hemostasis component. The hydrogel material is separated from the wound. Substantially all of the hemostatic product remains on the wound.Type: GrantFiled: November 12, 2014Date of Patent: January 31, 2017Assignee: St. Teresa Medical, Inc.Inventors: Curtis Olson, Tim Floyd, Phil Messina
-
Patent number: 9433682Abstract: Provided herein is a hydrogel composition comprising a graphene, a chitosan, and a polyethylene (glycol) diacrylate (PEGDA) (PCG hydrogel). In some embodiments, the hydrogel further comprises a N-isopropylacrylamide (NIPAM) (TPCG hydrogel). Also provided is a method for differentiating a mesenchymal stem cell comprising contacting the cell with the PCG hydrogel. Further provided herein is a method for delivering a pharmaceutical composition to a cell comprising administering to the cell a TPCG hydrogel and the pharmaceutical composition.Type: GrantFiled: February 25, 2013Date of Patent: September 6, 2016Assignees: University South Florida, National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS)Inventors: Subhra Mohapatra, Chunyan Wang
-
Patent number: 9433664Abstract: The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).Type: GrantFiled: September 19, 2011Date of Patent: September 6, 2016Assignee: MEDIMMUNE LIMITEDInventors: Ann Lovgren, Kenny Hansson
-
Patent number: 9399068Abstract: A viscoelastic hydrogel based on a protein hetero-assembled with a polymer is provided. The protein cannot self-assemble with itself and the polymer cannot self-assemble with itself. The protein has a first association sequence (1stA) and a first spacer (1stSp). The polymer has a second association sequence (2ndA) and a second spacer (2ndSp). The first association sequence and the second association sequence are physically cross-linked to interact with each other with a 1:1 known and specific stoichiometry to form a three dimensional scaffold. The protein is represented by {1stA(1stSp)}x1stA, where x is ?2, and the polymer is represented by {2ndA(2ndSp)}y2ndA, where y?2.Type: GrantFiled: April 20, 2015Date of Patent: July 26, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sarah C. Heilshorn, Widya Mulyasasmita, Lei Cai
-
Patent number: 9393347Abstract: A double-structured tissue implant and a method for preparation and use thereof for implantation into tissue defects. The double-structured tissue implant comprising a primary scaffold comprised of collagen and a secondary scaffold comprising a soluble collagen solution in combination with a surfactant generated and positioned within the primary scaffold. A process for preparation of the double-structured implant or the stand alone secondary scaffold comprising lyophilization and dehydrothermal treatment.Type: GrantFiled: February 7, 2014Date of Patent: July 19, 2016Assignee: Histogenics CorporationInventors: Hans P. i. Claesson, Laurence J. B. Tarrant, R. Lane Smith, Sonya Shortkroff
-
Patent number: 9393341Abstract: A stiffening layer for facilitating application of a plastic film to skin, the plastic film being a component in a wound dressing or other medical device and having the stiffening layer removably attached to one side thereof, at least a part of the other side of the film being provided with a layer of self-adhering adhesive. The stiffening layer is made of a stretchable material having a thickness of between 0.5-10 mm. The stiffening layer covers the whole area of the film and is divided into two or more portions by cutting line or lines.Type: GrantFiled: February 6, 2009Date of Patent: July 19, 2016Assignee: Mölnlycke Health Care ABInventors: Tomas Fabo, Anna Svensby
-
Patent number: 9387227Abstract: A composition for the topical treatment of sores, lesions, ulcers, and other disorders of the skin, said composition includes a combination of a bee product and caffeine. The bee product may comprise bee pollen, bee propolis, honey, or royal jelly. Variations of the composition may also contain a tannin. The composition may be in the form of an ointment or cream that is applied topically to an affected area of the body. The composition may also be used in other forms, such as a spray, shampoo, soap, lipstick, or adhesive bandage. The invention may also be useful as a health beverage.Type: GrantFiled: September 4, 2015Date of Patent: July 12, 2016Inventor: Gilbert Clinton Gee
-
Patent number: 9345803Abstract: An absorbent product intended particularly for use as a wound dressing comprises an admixture of carboxymethyl chitosan and chitosan wherein the chitosan incorporates at least one antimicrobial agent. Absorbency is provided by the carboxymethyl chitosan and antimicrobial properties by the antimicrobial agent incorporated in the chitosan.Type: GrantFiled: December 23, 2010Date of Patent: May 24, 2016Assignee: ADVANCED MEDICAL SOLUTIONS LIMITEDInventor: Colin Bradford
-
Patent number: 9339546Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.Type: GrantFiled: July 2, 2014Date of Patent: May 17, 2016Assignee: Advanced Bio-Technologies, Inc.Inventor: Paul Guilbaud
-
Patent number: 9333117Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.Type: GrantFiled: February 20, 2014Date of Patent: May 10, 2016Assignee: Z-MEDICA, LLCInventors: Raymond J. Huey, Denny Lo, Daniel J. Burns, Giacomo Basadonna, Francis X. Hursey
-
Patent number: 9327050Abstract: A hemostatic material as a high-performance medical material is described, which is capable of stopping bleeding in short time and is easy to handle and produce. The hemostatic material contains a nano-fiber that contains: a polymer, and a polypeptide having a peptide fragment represented by formula (1): -(Pro-Y-Gly)n-??(1) wherein Y represents hydroxyproline or proline, and n represents an integer ranging from 5 to 9000.Type: GrantFiled: March 22, 2013Date of Patent: May 3, 2016Assignee: JNC CORPORATIONInventors: Hisatoshi Kobayashi, Dohiko Terada, Masami Todokoro, Akiko Shimatani, Yukinori Kataoka
-
Patent number: 9321030Abstract: A film for the retention and controlled release of organic or inorganic molecules consists essentially of a phyllosilicate clay and a organic polyanion. The film may be a built-up layered film of alternating layers of the clay and the polyanion. Organic or inorganic molecules are absorbed into the film from solution, and released in response to changes in the film's environment. The film may be built up using layer-by-layer (LbL) methods, or deposited on a substrate from a mixture of the clay and polyanion. Articles may be coated with the film by the same methods. The film is useful for the controlled release of antibiotics in response to infections, and also retains antibiotics such that bacteria may be killed by direct contact with the film.Type: GrantFiled: December 18, 2012Date of Patent: April 26, 2016Assignee: The Trustees of the Stevens Institute of TechnologyInventors: Svetlana Sukhishvili, Svetlana Pavlukhina
-
Patent number: 9314420Abstract: The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue.Type: GrantFiled: September 14, 2012Date of Patent: April 19, 2016Inventor: Jan-Eric Ahlfors
-
Patent number: 9308173Abstract: The present invention provides novel slow-releasing ophthalmic compositions containing Povidone Iodine (PVP-I) and uses thereof in the treatment of acute infections of at least one eye tissue from bacterial, mycobacterial, viral, fungal, or amoebic causes and for preventing such infections in appropriate clinical settings. Each of the ophthalmic compositions contains povidone iodine, osmotic pressure regulator, suspending agent and EDTA-Na, wherein povidone iodine exists as microsphere particles formed by PVP-I and sodium alginate.Type: GrantFiled: November 28, 2012Date of Patent: April 12, 2016Assignee: IVIEW THERAPEUTICS, INC.Inventors: Bo Liang, John J. Baldwin, Yong Lu
-
Patent number: 9186436Abstract: Hydrogel-bacterial cellulose nano-composite materials are created using a hydrogel and never dried bacterial cellulose fibers. Such materials are suitable for a broad range of soft tissue replacement applications. In addition controlled release of bioactive agents properties can be designed into medical devices fabricated from such composite materials.Type: GrantFiled: July 10, 2008Date of Patent: November 17, 2015Assignee: AXCELON BIOPOLYMERS CORPORATIONInventors: Wan-Kei Wan, Leonardo Millon
-
Patent number: 9174839Abstract: The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polyelectrolytes to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound.Type: GrantFiled: February 10, 2011Date of Patent: November 3, 2015Assignee: IMBED BIOSCIENCES, INC.Inventors: Nicholas L. Abbott, Ankit Agarwal, Christopher J. Murphy, Jonathan F. McAnulty
-
Patent number: 9120295Abstract: Chitosan films that have been treated with a polyhydroxyalkyl compound and washed, and laminates made from the films are provided. This treatment lessens the film shrinkage. The films and laminates can be used to make a variety of finished articles that can be used to provide protection from hazardous chemical and biological agents.Type: GrantFiled: June 9, 2008Date of Patent: September 1, 2015Assignee: E I DU PONT DE NEMOURS AND COMPANYInventor: Edward George Howard, Jr.
-
Patent number: 9078782Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.Type: GrantFiled: February 5, 2013Date of Patent: July 14, 2015Assignee: Z-MEDICA, LLCInventors: Raymond J. Huey, Denny Lo, Daniel J. Burns, Giacomo Basadonna, Francis X. Hursey
-
Patent number: 9074214Abstract: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.Type: GrantFiled: July 30, 2013Date of Patent: July 7, 2015Assignee: NOXXON Pharma AGInventors: Axel Vater, Christian Maasch, Sven Klussmann, Werner Purschke, Dirk Eulberg, Florian Jarosch, Klaus Buchner
-
Patent number: 9040076Abstract: The present invention provides switchable adhesives comprising a mixture, in proportions by weight, of 20% to 98% of an adhesive, 2% to 80% of curable molecules and 0.05% to 10% of photoinitiator in which the weight proportion of the adhesive is calculated on the basis of its dry weight and wherein the adhesive includes an internal cross-linker for cross-linking the adhesive during drying to provide a cohesive strength of between 5 and 100 N/12.7×12.7 mm measured according to FINAT test method No. 18. Preferably, the adhesive and curable molecules are mutually soluble when dry, or the curable molecules and adhesive may be uniformly dispersed in each other. Preferably the amount of adhesive in the mixture is in the range 40% to 98% by weight, more preferably 60% to 95% by weight, even more preferably 70% to 85% by weight. Preferably the proportion of curable molecules in the mixture ranges from 2% to 60% by weight, more preferably 5% to 40% by weight, even more preferably 15% to 30 by weight.Type: GrantFiled: March 31, 2011Date of Patent: May 26, 2015Assignee: Lumina Adhesives ABInventor: Mats Tunius
-
Publication number: 20150132363Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm2 of the wound facing surface of the dressing and 13.0 mg/cm2 of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue.Type: ApplicationFiled: January 18, 2015Publication date: May 14, 2015Inventors: Martin MacPhee, Dawson Beall
-
Publication number: 20150125512Abstract: A sheet material that can be used as a wound dressing and contains elemental metal particles.Type: ApplicationFiled: February 26, 2013Publication date: May 7, 2015Inventors: Marco Wolfstaedter, Birgit Schaefer
-
Publication number: 20150118284Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.Type: ApplicationFiled: December 24, 2014Publication date: April 30, 2015Inventors: Martin MacPhee, Dawson Beall
-
Publication number: 20150118283Abstract: The invention relates to a wound dressing which is particularly suitable for therapeutically dressing wounds. Said wound dressing comprises at least one wound covering layer and at least one sorbent based on an activated carbon which has a biocidal and/or biostatic, in particular antimicrobial effect and/or finish.Type: ApplicationFiled: August 31, 2012Publication date: April 30, 2015Inventors: Hasso Von Blücher, Raik Schönfeld, Frank Pallaske
-
Patent number: 9017717Abstract: A bandage includes a reservoir filled with a perfluorochemical fluid, saturated with oxygen. Oxygen passes through a permeable membrane to the skin or wound to promote healing, and carbon dioxide travels from the skin or wound to the reservoir.Type: GrantFiled: April 6, 2006Date of Patent: April 28, 2015Assignee: Peach Technologies LLCInventors: Thomas H. Shaffer, Robert G. Stern, Marla R. Wolfson
-
Patent number: 9011901Abstract: The present invention provides hemostatic compositions comprising components of the flowers of pharmaceutical chamomile (Chamomilla recutita) and the leaves of dioecious nettle (Urtica dioica). Further inclusion of a biocompatible polymeric base, particularly an alignate, generates a composition with excellent and broad spectrum hemostatic capabilities, with concurrent antiseptic and anti-inflammatory properties. The invention further provides methods of using the inventive compositions in to reduce or stop bleeding, as well as a variety of apparatuses useful in hemostatic contexts that incorporate the inventive compositions. In one particular embodiment, the invention provides hemostatic dressings in which a polymeric layer incorporating chamomile and nettle components is applied to a textile or fabric material, for example a non-woven viscose.Type: GrantFiled: December 19, 2012Date of Patent: April 21, 2015Inventor: Linda Eastwood
-
Publication number: 20150104496Abstract: The present invention relates to a composition containing at least one nutritive, at least one disinfecting or decontaminating and/or at least one protease-inhibiting active compound and/or active compound complex for the external care and/or treatment of wounds of the human or animal body.Type: ApplicationFiled: October 21, 2014Publication date: April 16, 2015Inventor: Birgit RIESINGER
-
Publication number: 20150098985Abstract: A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).Type: ApplicationFiled: October 6, 2014Publication date: April 9, 2015Inventors: BREDA MARY CULLEN, SARA JAYNE GREGORY
-
Patent number: 8999377Abstract: Biocompatible foams having excellent physical and chemical properties are described. The biocompatible foams can be formed in situ or applied as a pre-formed foam for the treatment of tissue. The invention provides biocompatible degradable foams formed with a poly-?(1?4)glucopyranose macromer. The invention also provides biostable foams formed with a poly(alkylene oxide) macromer.Type: GrantFiled: September 19, 2008Date of Patent: April 7, 2015Assignee: Surmodics, Inc.Inventors: Emily R. Rolfes, Pamela J. Reed
-
Patent number: 8999297Abstract: A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.Type: GrantFiled: July 13, 2009Date of Patent: April 7, 2015Assignee: Inter-Med, Inc.Inventors: Gary J. Pond, John Baeten